PHILADELPHIA — Among patients with type 2 diabetes and confirmed CVD at baseline, treatment with once-weekly exenatide reduced the risk for major adverse CV events, with no new or overall safety concerns related to cardiac events, according to a prespecified subgroup analysis of the EXSCEL study.
“We were interested in exploring clinical outcomes with exenatide once weekly in the [approximate] 70% of the [EXSCEL] cohort with known CVD at baseline,” Robert J. Mentz, MD, associate professor of medicine, director of the Duke Cooperative Cardiovascular Society and associate program director at the Duke Cardiovascular Disease Fellowship, told Healio. Mentz, a Cardiology Today Next Gen Innovator, presented the subgroup data at the third annual Heart in Diabetes conference.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.